Barely Significant
← all excerpts

Recent Anti-KRAS<sup>G12D</sup> Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma.

Cancers (Basel) · 2025 · PMC11853620 · PMID 40002297

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

a positive trendno p-value reported
A phase II clinical trial testing GI-4000 against KRAS G12C/D/V in lung carcinoma showed that 50% of patients showed an immune response to mutant KRAS G12C/D/V , and overall survival showed a positive trend [ 118 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.